Stock Analiz

Lifeward Ltd. LFWD

Industrial Specialties · IPO 2014 · data as of November 13, 2026

$4.06Market cap $11M
Open the interactive analysis →

Lifeward Ltd. (LFWD) is a healthcare company listed in the US with a market value of about $11M. In the twelve months to September 30, 2026 it had revenue of $21M and net income of -$33M, a net margin of -155.4%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 38% a year, a 5-year average ROIC of -70%.

About Lifeward

Lifeward is listed in the US and classified in industrial specialties, IPO year 2014. Revenue went from $4M in 2014 to $22M in 2025, growth of about 16.9% a year. It was profitable in 0 of the last 10 years in our data. It spends 15% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.5
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-170.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-14.1%
Revenue growth (5 yrs, per year)38.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-186.3%
ROIC (5-yr avg.)-70.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$21M$22M$26M$14M$6M$6M$4M$5M$7M$8M$6M
Net income-$33M-$20M-$29M-$22M-$20M-$13M-$13M-$16M-$22M-$25M-$33M
Free cash flow-$20M-$17M-$22M-$21M-$18M-$12M-$13M-$15M-$15M-$22M-$27M
EPS (diluted)$-15.43$-7.03$-10.22$-7.82$-6.91$-4.50$-4.58$-5.49$-7.65$-8.73$-11.48
Net margin-155.4%-90.4%-112.8%-159.8%-355.1%-213.5%-295.4%-319.1%-331.2%-318.8%-553.8%
ROIC—-153.3%-117.5%-48.8%-21.9%-11.1%-40.6%-56.3%-180.7%-91.2%-91.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $20.00, 393% above the current price; targets range from $10.00 to $30.00; the consensus rating is “none”; expected EPS is $-5.02 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Lifeward pay a dividend?

Not currently.

Is Lifeward a good stock to buy?

We do not give buy or sell advice. Lifeward scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.